NantHealth, Inc. empowers the creation of integrated healthcare delivery networks. In developing technology that supports systems and data, NantHealth enable efficiency, personalized treatment, and collaboration across health care.

According to the law firm press release, the Complaint alleges throughout the Class Period, Defendants made false and/or misleading statements, and failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose: (1) that Defendant had donated funds through nonprofit organizations to the University of Utah for the purpose of funneling those funds back into NantHealth; (2) that, as such, the Company and Defendant participated in the violation of federal tax laws — exposing the Company to possible civil and criminal liability; (3) that the Company improperly recorded orders received from the University of Utah as GPS Cancer test orders; (4) that, as a result, the Company reported false and inflated GPS Cancer order figures for the third quarter of 2016; and (5) that, as a result of the foregoing, the Company’s financial statements and Defendants’ statements about NantHealth’s business, operations, and prospects were materially false and misleading.

An amended and consolidated Complaint was filed on June 26, 2017. Defendants filed a Motion to Dismiss the amended Complaint on August 2. On March 27, 2018, the Court issued an Order granting in part and denying in part Defendants' Motion to Dismiss.

On October 23, 2019, the parties filed a notice stating they had reached a Settlement in principle. On December 9, the parties entered into a Stipulation of Settlement. On January 31, 2020, the Court issued preliminary approval of the Settlement. On September 10, the Court granted final approval of the Settlement and entered Final Judgment. The Court issued an Order granting Plaintiffs' Motion for disbursement of Settlement Funds on January 12, 2021. The Court issued an Order authorizing distribution of the remaining Settlement Funds to the designated Cy Pres recipient on December 8.